IPCA Laboratories Q4 Results Live : IPCA Laboratories announced their Q4 results on 29 May, 2024. The company reported a 34.49% increase in revenue year-over-year, but saw a 22.12% decrease in profit compared to the same period last year.
Quarterly comparisons show a 0.97% decline in revenue and a significant 66.87% decrease in profit from the previous quarter.
Selling, general & administrative expenses went up by 1.52% sequentially and by 42.37% year-over-year.
Operating income took a hit, declining by 62.45% quarter-over-quarter and 21.93% year-over-year.
The earnings per share (EPS) for Q4 stood at ₹5.85, marking a 94.06% increase from the previous year.
In terms of market performance, IPCA Laboratories delivered -1.86% return in the last week, 15.45% return in the last 6 months, and a YTD return of 16.25%.
The company currently boasts a market capitalization of ₹32,829.33 Cr, with a 52-week high/low of ₹1374.6 & ₹685.8 respectively.
Analysts covering IPCA Laboratories have mixed opinions, with 3 analysts rating it as Strong Sell, 2 as Sell, 3 as Hold, 4 as Buy, and 2 as Strong Buy. The consensus recommendation as of 30 May, 2024, was to Hold.
IPCA Laboratories Financials
Period | Q4 | Q3 | Q-o-Q Growth | Q4 | Y-o-Y Growth |
---|---|---|---|---|---|
Total Revenue | 2033.01 | 2052.86 | -0.97% | 1511.63 | +34.49% |
Selling/ General/ Admin Expenses Total | 466.01 | 459.04 | +1.52% | 327.33 | +42.37% |
Depreciation/ Amortization | 98.13 | 99.5 | -1.38% | 69.54 | +41.11% |
Total Operating Expense | 1945.96 | 1821.03 | +6.86% | 1400.13 | +38.98% |
Operating Income | 87.05 | 231.83 | -62.45% | 111.5 | -21.93% |
Net Income Before Taxes | 76.6 | 288.89 | -73.48% | 129.44 | -40.82% |
Net Income | 59.59 | 179.88 | -66.87% | 76.52 | -22.12% |
Diluted Normalized EPS | 5.85 | 6.99 | -16.27% | 3.02 | +94.06% |
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.